文献速递肾小球疾病

原发性IgA肾病治疗:变革、变革、变革

The Treatment of Primary IgA Nephropathy: Change, Change, Change.
PubMed 文献 · Am J Kidney Dis · 2023-09-23

IgA肾病是全球最常见的肾小球疾病,但治疗策略仍存争议。过去十年临床试验激增,包括2种新获批疗法,SGLT2抑制剂在蛋白尿性CKD中有效,IgA肾病可能也不例外。内皮素阻断、补体抑制和B细胞靶向等新药前景可观,本文提出当今治疗路径并讨论未来可能出现的治疗。

要点

  • 过去十年IgA肾病临床试验激增,包括2种新获批疗法。
  • SGLT2抑制剂在蛋白尿性CKD中有效,IgA肾病可能也不例外。
  • 内皮素阻断、补体抑制和B细胞靶向等新药前景可观。

核心结论

  • IgA肾病治疗策略的变革似乎不可避免,当前是令人兴奋和乐观的时期。

研究设计与样本

  • 综述性文章,未报告系统检索范围或样本量。

主要发现

  • 过去十年临床试验激增,包括2种新获批疗法。
  • SGLT2抑制剂在蛋白尿性CKD中有效,IgA肾病可能也不例外。
  • 内皮素阻断、补体抑制和B细胞靶向等新药前景可观。

关键数值与推荐

  • 原文未汇总具体标准与数值。

临床怎么用

  • 本文提出当今治疗IgA肾病患者的路径,并讨论未来可能出现的治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IgA nephropathy (IgAN) is the most common glomerular disease in the world. However, the approach to treatment remains controversial. There has been an explosion of clinical trials over the past decade both to further examine corticosteroid use and usher in additional treatment considerations, including 2 newly approved therapies for IgAN. Sodium glucose cotransporter 2 inhibitors are proving to be effective therapy across proteinuric chronic kidney diseases, and IgAN is not likely to be an exception. Further supportive agents are looking highly promising and so are novel agents that specifically focus on the pathophysiology of this disease, including endothelin blockade, complement inhibition, and B-cell targeted strategies. We suggest a present-day approach to treatment of individuals with IgAN, expose the limitations in our knowledge, and discuss new treatments that may arise, hoping they come with evidence about optimal utilization. Change appears to be inevitable for our approach to the treatment of IgA nephropathy. This is truly an exciting and optimistic time.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Caster DJ, Lafayette RA. The Treatment of Primary IgA Nephropathy: Change, Change, Change. Am J Kidney Dis. 2023. PMID: 37742867. doi:10.1053/j.ajkd.2023.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。